Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic CD3-depleted CD19-enriched B-cell concentrate
- Development stage
- Unknown
- Lead developer
- Universitätsklinikum Erlangen
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic CD3-depleted CD19-enriched B-cell concentrate is an investigational adoptive cellular immunotherapy developed by Universitätsklinikum Erlangen. It consists of GMP-manufactured, cryopreserved B-lymphocytes derived from healthy, donor-identical stem cell donors. The manufacturing process utilizes the CliniMACS system for a two-step immunomagnetic separation: first depleting T cells (CD3+) and then positively selecting B cells (CD19+). The product is intended for patients following allogeneic hematopoietic stem cell transplantation to accelerate the reconstitution of humoral immunity and enhance vaccine responses.
- Other names
- allogeneic B-cell concentratedonor-derived B-cell concentrateCD3-depleted CD19-enriched B-cell concentrateCD-3-depleted CD19-enriched B-cell concentrateCD 3-depleted CD19-enriched B-cell concentrate
Beyond the preview
Go deeper on allogeneic CD3-depleted CD19-enriched B-cell concentrate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic CD3-depleted CD19-enriched B-cell concentrate.